Patent clearance storefront · analysed by hand
+7 (916) 709-0125 work@pctguru.ru
Patent clearance storefront · by INN

Patent analytics for a molecule — in minutes

Pick an INN — get a ready patent clearance report: patent statuses, what can be worked around or challenged, and safe generic launch dates. Compiled by specialists, by hand.

20
molecules
in the storefront
100%
analysis
done by humans
.pdf
ready report
right after payment
Day-1
safe generic
launch dates
New additions

Until the next patent reports

We add 1 to 3 new molecules every week. The next batch is coming soon.

00days
:
00hours
:
00minutes
:
00seconds
Why the storefront

More than just a search

We review almost a dozen databases to gather exhaustive information on a molecule and not miss a single important patent document. Modern databases make searching easier, but it is our team of specialists that selects only what is genuinely relevant to the molecule, its use and its form.

Patent statuses

What is an absolute blocker, what can be worked around or challenged, and what poses no threat.

Day-One Launch

Dates when a generic or biosimilar can be safely launched, with explanations.

Ready .pdf

A competitive-intelligence and patent dossier: market, competitors, RF/EAPO patents and entry opportunities — in a single PDF.

Currency

A search is current as of its date and for about six months, after which it is updated.

Storefront

Featured molecules

Patent clearance report
Реслизумаб (Cinqair®) — конкурентная разведка и патентный анализ РФ/ЕАПВ

Готовый аналитический отчёт по реслизумабу (Cinqair®/Cinqaero®) — гуманизированному моноклональному антителу против IL-5 (Teva) для дополнительной терапии тяжёлой эозинофильной астмы. В одном PDF:…

20 000 Details
Patent clearance report
Инаксаплин (VX-147) — патентно-аналитический обзор РФ/ЕАПВ (исследуемый препарат)

Готовый аналитический отчёт по инаксаплину (VX-147) — исследуемому пероральному ингибитору канала APOL1 (Vertex) для APOL1-опосредованной болезни почек. На момент подготовки препарат не…

16 500 Details
Patent clearance report
Меглюмина акридонацетат (Циклоферон®, таблетки ППО) — патентный анализ РФ/ЕАПВ

Готовый аналитический отчёт по меглюмина акридонацетату (Циклоферон®, таблетки ППО) — низкомолекулярному индуктору интерферона (НТФФ «Полисан») для иммуномодулирующей и противовирусной терапии. В одном…

10 000 Details
Patent clearance report
Пиротиниб (Irene®) — конкурентная разведка и патентный анализ РФ/ЕАПВ

Готовый аналитический отчёт по пиротинибу (Irene®) — пероральному необратимому ингибитору тирозинкиназы HER2/EGFR (Jiangsu Hengrui, КНР) для терапии HER2-положительного рака молочной железы. В…

25 000 Details
Patent clearance report
Элиглустат (Cerdelga®) — конкурентная разведка и патентный анализ РФ/ЕАПВ

Готовый аналитический отчёт по элиглустату (Cerdelga®) — пероральному ингибитору глюкозилцерамид-синтазы (Sanofi Genzyme) для длительной терапии болезни Гоше 1 типа у взрослых с…

16 500 Details
Patent clearance report
Ломитапид (Juxtapid®) — конкурентная разведка и патентный анализ РФ/ЕАПВ

Готовый аналитический отчёт по ломитапиду (Juxtapid®/Lojuxta®) — пероральному ингибитору микросомального белка-переносчика триглицеридов (MTP) (Amryt/Chiesi) для снижения ЛПНП при гомозиготной семейной гиперхолестеринемии. В…

16 500 Details
All molecules in the storefront
Report structure

Competitive intelligence and patent analysis — seven sections

The report has grown from a list of patents into a full dossier: the molecule’s commercial profile, the competitive landscape and a patent breakdown for RF/EAPO with an assessment of entry opportunities. It opens with a short summary and methodology, followed by seven numbered thematic sections.

00

Summary and methodology

A short digest: what the molecule is, who the originator is, the key takeaways and how the report was built — sources and their statuses.

01

Drug overview

INN, trade name, development code, mechanism of action, modality (small molecule or biologic), formula and structure.

02

Development history

A year-by-year timeline: discovery of the molecule, pivotal trials, regulatory approvals and the expansion of indications.

03

Market significance

Therapeutic value, uniqueness of the mechanism, sales and their dynamics, and the position on the Russian/CIS market.

04

Competitive landscape

Direct generics or biosimilars and indirect in-class competitors, including Russian players.

05

Patent protection — RF/EAPO

A breakdown of the originator’s IP: what blocks, what can be worked around or challenged — with an assessment of each.

06

Entry opportunities — freedom to operate

Entry strategies by protection layer: indication carve-outs, formulation design-arounds, challenges and Bolar-exemption preparation.

07

Routes of synthesis or manufacture

For small molecules — synthesis routes and key raw materials; for biologics — the manufacturing paradigm. No reproducible protocols.

Full report structure
PCT GURU
Patent bureau
  • №2372Russian patent attorney
  • №613Eurasian patent attorney
  • с 2010Intellectual property in pharma
Who prepares the analysis

Instant search — backed by a full-service bureau

The storefront is a unique service giving instant access to a patent search by INN. At the same time PCT GURU operates as a full-service patent bureau: the team includes not only patent specialists but also lawyers, marketers and designers, and works with scientists, technologists and specialists in the registration of supplements and medicines.

All bureau services →

Can’t find the molecule you need?

Write to us — we’ll prepare a patent clearance report for your INN and add it to the storefront.